GlobeImmune (NASDAQ:GBIM) has climbed 170.49% in the past week and advanced 150% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 173.74% and the outperformance has advanced to 147.72% for the last 4 weeks period.
GlobeImmune (NASDAQ:GBIM): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.89 and $1.89 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $3.38. The buying momentum continued till the end and the stock did not give up its gains. It closed at $3.30, notching a gain of 60.98% for the day. The total traded volume was 14,507,635 . The stock had closed at $2.05 on the previous day.
The company shares have rallied 17.44% from its 1 Year high price. On Dec 2, 2015, the shares registered one year high at $6.30 and the one year low was seen on Mar 7, 2016. The 50-Day Moving Average price is $1.49 and the 200 Day Moving Average price is recorded at $2.33.
On the companys insider trading activities,The director of Globeimmune Inc, Torres S. Edward sold 26,188 shares at $1.67 on March 17, 2016. The Insider selling transaction had a total value worth of $43,734. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Currently the company Insiders own 23.5% of GlobeImmune shares according to the proxy statements. Institutional Investors own 12.37% of GlobeImmune shares.
GlobeImmune, Inc. (GlobeImmune) is a biopharmaceutical company. The Company is focused on developing therapeutic products for cancer and infectious diseases based on its Tarmogen platform. The Company has four Tarmogen product candidates in five ongoing clinical trials. The Company has two collaborations with biotechnology companies. Gilead Sciences, Inc. (Gilead), exclusively licenses product candidates to treat chronic hepatitis B virus (HBV) infection. Celgene Corporation (Celgene) entered into collaboration with the Company for certain oncology product candidates. Celgene exercises its option for across the world, exclusive license to the GI-6300 program, which is a Tarmogens program targeting the brachyury protein. The Company has no products approved for commercial sale, and as of September 30, 2014, it has not generated any product revenue.